Development of a pharmacovigilance safety monitoring tool for the rollout of single low-dose primaquine and artemether-lumefantrine to treat Plasmodium falciparum infections in Swaziland: A pilot study

Malaria Journal

Volumn 15, Issue 1, 2016, Pages

  Poirot, Eugenie ^a,b   Soble, Adam ^c   Ntshalintshali, Nyasatu ^c   Mwandemele, Asen ^d   Mkhonta, Nomcebo ^e   Malambe, Calisile ^e   Vilakati, Sibonakaliso ^e   Pan, Sisi ^c   Darteh, Sarah ^f   Maphalala, Gugu ^g   Brown, Joelle ^a,b   Hwang, Jimee ^a,h   Pace, Cheryl ⁱ   Stergachis, Andy ^j   Vittinghoff, Eric ^b   Kunene, Simon ^e   Gosling, Roland ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CLINTON HEALTH ACCESS INITIATIVE   (United States)

^d UNIVERSITY OF NAMIBIA   (Namibia)

^e National Malaria Control Programme   (Swaziland)

^f International Center for AIDS Care and Treatment Programs   (Swaziland)

^g Swaziland Health Laboratory Services   (Swaziland)

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

ⁱ LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^j UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

Elimination; G6PD; Glucose 6 phosphate dehydrogenase deficiency; Malaria; Pharmacovigilance; Plasmodium falciparum; Primaquine; Safety

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; HEMOGLOBIN; PRIMAQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE;

ABDOMINAL CRAMP; ADULT; AGED; ANEMIA; ARTICLE; BACKACHE; CHILD; CHILL; COUGHING; DIARRHEA; DIZZINESS; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; FEVER; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEADACHE; HOSPITALIZATION; HUMAN; JAUNDICE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MIDDLE AGED; MORTALITY; PILOT STUDY; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; SIDE EFFECT; SINGLE DRUG DOSE; SWAZILAND; VOMITING; WEAKNESS; YOUNG ADULT; ADOLESCENT; DRUG COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; INFANT; MALARIA, FALCIPARUM; PATHOLOGY; POSTMARKETING SURVEILLANCE; PROCEDURES; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PHARMACOVIGILANCE; PILOT PROJECTS; PRIMAQUINE; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; SWAZILAND; YOUNG ADULT;

EID: 84979645629     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-016-1410-7     Document Type: Article

References (28)

1. White NJ. Primaquine to prevent transmission of falciparum malaria. Lancet Infect Dis. 2013;13:175-81.
2. Bousema JT, Schneider P, Gouagna LC, Drakeley CJ, Tostmann A, Houben R, et al. Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. J Infect Dis. 2006;193:1151-9.
3. Drakeley CJ, Jawara M, Targett GA, Walraven G, Obisike U, Coleman R, et al. Addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in Gambian children causes a significant but short-lived reduction in infectiousness for mosquitoes. Trop Med Int Health. 2004;9:53-61.
4. Targett G, Drakeley C, Jawara M, von Seidlein L, Coleman R, Deen J, et al. Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. J Infect Dis. 2001;183:1254-9.
5. Baird JK, Schwartz E, Hoffman SL. Prevention and treatment of vivax malaria. Curr Infect Dis Rep. 2007;9:39-46.
6. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg. 2006;75:402-15.
7. Bousema T, Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev. 2011;24:377-410.
8. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371:64-74.
9. Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar J. 2014;13:418.
10. Kellermeyer RW, Tarlov AR, Brewer GJ, Carson PE, Alving AS. Hemolytic effect of therapeutic drugs. Clinical considerations of the primaquine-type hemolysis. JAMA. 1962;180:388-94.
11. Luzzatto L, Seneca E. G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. Br J Haematol. 2014;164:469-80.
12. Updated WHO policy recommendation: single dose Primaquine as a gametocytocide in Plasmodium falciparum malaria. Geneva: World Health Organization; 2012. (Press release).
13. White NJ, Qiao LG, Qi G, Luzzatto L. Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malar J. 2012;11:418.
14. Talisuna AO, Staedke SG, D'Alessandro U. Pharmacovigilance of antimalarial treatment in Africa: is it possible? Malar J. 2006;5:50.
15. Recht J, Ashley E, White N. Safety of 8-aminoquinoline antimalarial medicines. Geneva: World Health Organization; 2014.
16. Agency EM. ICH Topic E 2 A: clinical safety data management: definitions and standards for expedited reporting. 1995.
17. WHO. Toxicity grading scale for determining the severity of adverse events. Geneva: World Health Organization; 2003.
18. Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350:552-9.
19. Malaria Surveillance Database System (Internet).
20. WHO. Management of severe malaria: a practical handbook. 3rd ed. Geneva: World Health Organization; 2012.
21. WHO. Haemoglobin concentrations for the diagnosis of anemia and assessment of severity. Geneva: World Health Organization; 2011.
22. Bukirwa H, Nayiga S, Lubanga R, Mwebaza N, Chandler C, Hopkins H, et al. Pharmacovigilance of antimalarial treatment in Uganda: community perceptions and suggestions for reporting adverse events. Trop Med Int Health. 2008;13:1143-52.
23. Hall CS, Fottrell E, Wilkinson S, Byass P. Assessing the impact of mHealth interventions in low- and middle-income countries - what has been shown to work? Glob Health Action. 2014;7:25606.
24. Zurovac D, Talisuna AO, Snow RW. Mobile phone text messaging: tool for malaria control in Africa. PLoS Med. 2012;9:e1001176.
25. Das J, Hammer J, Sanchez-Paramo C. The impact of recall periods on reported morbidity and health seeking behavior. J Dev Econ. 2012;98:76-88.
26. Domingo GJ, Satyagraha AW, Anvikar A, Baird K, Bancone G, Bansil P, et al. G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. Malar J. 2013;12:391.
27. Chen I, Poirot E, Newman M, Kandula D, Shah R, Hwang J, et al. An assessment of the supply, programmatic use, and regulatory issues of single low-dose primaquine as a Plasmodium falciparum gametocytocide for sub-Saharan Africa. Malar J. 2015;14:204.
28. Chen IT, Gosling RD. Targeting Plasmodium falciparum transmission with primaquine: same efficacy, improved safety with a lower dose? Expert Rev Clin Pharmacol. 2014;7:681-6.